Last update 21 Mar 2025

Dubermatinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Dubermatinib (USAN/INN), Dubermatinib Tartrate, TP-0903
Target
Action
inhibitors
Mechanism
AXL inhibitors(AXL receptor tyrosine kinase inhibitors)
Originator Organization
Active Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC24H30ClN7O2S
InChIKeyYUAALFPUEOYPNX-UHFFFAOYSA-N
CAS Registry1341200-45-0

External Link

KEGGWikiATCDrug Bank
D11732--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Small Lymphocytic LymphomaPhase 2
United States
10 Jun 2019
Chronic Lymphocytic LeukemiaPhase 2
United States
10 Jun 2019
Acute Myeloid Leukemia with FLT3/ITD MutationPhase 1
United States
05 Nov 2020
Relapsing acute myeloid leukemiaPhase 1
United States
05 Nov 2020
Treatment related acute myeloid leukaemiaPhase 1
United States
05 Nov 2020
Advanced Malignant Solid NeoplasmPhase 1
United States
14 Dec 2016
BRAF Mutation colorectal cancersPhase 1
United States
14 Dec 2016
BRAF V600 mutation-positive MelanomaPhase 1
United States
14 Dec 2016
EGFR positive non-small cell lung cancerPhase 1
United States
14 Dec 2016
Recurrent ovarian cancerPhase 1
United States
14 Dec 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
27
ssqdqirlpf(mlyoqcawri) = iglxymhuln zflalovhil (virbhhjjii, 11.8–61.6)
-
08 Jun 2023
ssqdqirlpf(mlyoqcawri) = yxkhkfrbsa zflalovhil (virbhhjjii, 21.1–78.9)
Phase 1/2
Acute Myeloid Leukemia
First line
TP53 Mutation
16
nerypezsdz(mfnezzatff) = miyvewbtlr wdehelhbyz (kheikxonoh, 15.2 - 64.6)
Positive
02 Jun 2022
Phase 1/2
3
(TP-0903 Monotherapy (25mg Dose of TP-0903))
zmlslpxhct(fdizieyyif) = chflppqrwk xgactklacw (dxjfhflwur, vmqtrafgyr - xufxmcvjka)
-
02 Feb 2021
(TP-0903 and Ibrutinib Combination Therapy (20 mg Dose of TP-0903))
zmlslpxhct(fdizieyyif) = aonmjqfhja xgactklacw (dxjfhflwur, amxqmmoqzf - pgmxpzdzfl)
Not Applicable
-
otqcwekwrs(ikesstybvn) = iiofhxhrnw xkvhfyimwo (vlvlznvazg )
-
15 Feb 2019
Placebo
otqcwekwrs(ikesstybvn) = amvagyfrnz xkvhfyimwo (vlvlznvazg )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free